Clinical Trials

Numerous clinical trials evaluate the therapeutic efficacy, safety, and pharmacokinetics of favipiravir across Phase 1 through Phase 4 studies for conditions including COVID-19, human influenza, Lassa fever, Crimean-Congo hemorrhagic fever, and hepatic impairment, alongside evaluations in healthy volunteers. Sponsored by academic, governmental, and commercial entities—such as the Institut National de la Sante Et de la Recherche Medicale, the Liverpool School of Tropical Medicine, and FUJIFILM Toyama Chemical Co. Ltd.—this global research portfolio encompasses actively recruiting, completed, and terminated studies.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT06860334 RECRUITING
Crimean-Congo Hemorrhagic Fever
Liverpool School of Tropical Medicine
 2026-06-04 PHASE2
NCT06024421 RECRUITING
Infectious Disease; Pharmacology
Institut National de la Santé Et de la Recherche Médicale, France
 2024-05-14 PHASE1
NCT06212336 RECRUITING
Lassa Fever
Irrua Specialist Teaching Hospital
 2025-05-02 PHASE2; PHASE3
NCT04746183 RECRUITING
Covid19
University of Liverpool
 2020-07-03 PHASE1; PHASE2
NCT05648448 RECRUITING
Influenza; Influenza, Human
University of Oxford
 2023-02-22 PHASE2
NCT06488300 RECRUITING
Respiratory Syncytial Virus; Respiratory Syncytial Virus, Human
University of Oxford
 2024-07-25 PHASE2
NCT05041907 RECRUITING
COVID-19
University of Oxford
 2021-09-30 PHASE2
NCT06024421 Recruiting
Infectious Disease|Pharmacology
Institut National de la Santé Et de la Recherche Médicale France|FUJIFILM Toyama Chemical Co. Ltd.
 2024-04 Phase 1
NCT05940545 UNKNOWN
CCHF
Liverpool School of Tropical Medicine
 2023-07-12 PHASE1; PHASE2
NCT05940545 Recruiting
CCHF
Liverpool School of Tropical Medicine
 2023-07-12 Phase 1|Phase 2
NCT04918927 COMPLETED
Covid19
Coordinación de Investigación en Salud, Mexico
 2021-10-12 PHASE2
NCT04784559 TERMINATED
COVID-19 Infection
PharmaMar
 2021-06-04 PHASE3
NCT05502081 COMPLETED
COVID-19
Mansoura University Hospital
 2022-09-02 PHASE4
NCT05279235 TERMINATED
Moderate to Severe COVID-19
Shanghai Vinnerna Biosciences Co., Ltd.
 2022-03-14 PHASE3
NCT04907682 COMPLETED
Lassa Fever
Bernhard Nocht Institute for Tropical Medicine
 2021-07-30 PHASE2
NCT05155527 UNKNOWN
COVID-19
Mahidol University
 2022-02-10 PHASE2
NCT04718285 UNKNOWN
COVID-19; SARS-CoV-2
Bahçeşehir University
 2021-05-15 PHASE2
NCT04475991 TERMINATED
COVID-19
Hospital General de México Dr. Eduardo Liceaga
 2021-07-13 PHASE2
NCT05185284 COMPLETED
COVID-19
Promomed, LLC
 2021-08-11 PHASE3
NCT05417997 COMPLETED
COVID-19 Respiratory Infection; FLU; Cold; Influenza; Bacterial Pneumonia; COVID-19 Pneumonia
RAAS Nutritionals, LLC
 2021-05-29 PHASE3
NCT04499677 COMPLETED
COVID-19
University College, London
 2020-09-24 PHASE2
NCT04940871 TERMINATED
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
University of Pecs
 2021-11-25 PHASE2
NCT04445467 UNKNOWN
COVID
Bayside Health
 2020-07-30 PHASE2
NCT04448119 TERMINATED
COVID-19; SARS-CoV-2
Appili Therapeutics Inc.
 2020-10-16 PHASE2
NCT04613271 COMPLETED
Infectious Disease; SARS-CoV Infection; Covid19
Ina-Respond
 2020-10-15 PHASE3
NCT04600895 COMPLETED
Covid19
Appili Therapeutics Inc.
 2020-11-30 PHASE3
NCT04828564 UNKNOWN
SARS-CoV2; COVID-19
The Scientific and Technological Research Council of Turkey
 2021-04 PHASE2; PHASE3
NCT05014373 UNKNOWN
Covid19
University of the Philippines
 2020-10-12 PHASE3
NCT04303299 COMPLETED
SARS-COV-2 Infections; COVID-19
Department of Medical Services Ministry of Public Health of Thailand
 2020-08-19 PHASE3
NCT04532931 COMPLETED
COVID-19
Shin Poong Pharmaceutical Co. Ltd.
 2020-09-03 PHASE2
NCT04464408 COMPLETED
COVID-19
King Abdullah International Medical Research Center
 2020-07-23 PHASE2; PHASE3
NCT04818320 COMPLETED
Covid19
Penang Hospital, Malaysia
 2021-02-16 PHASE3
NCT04907682 Completed
Lassa Fever
Bernhard Nocht Institute for Tropical Medicine|University of Hamburg-Eppendorf|Alliance for International Medical Action|Institut National de la Santé Et de la Recherche Médicale France|University of Bordeaux|Federal Medical Centre Owo|Irrua Specialist Teaching Hospital
 2021-07-30 Phase 2
NCT04373733 COMPLETED
Coronavirus Infection
Chelsea and Westminster NHS Foundation Trust
 2020-05-01 PHASE3
NCT04346628 COMPLETED
Sars-CoV2; COVID-19
Stanford University
 2020-07-12 PHASE2
NCT04694612 UNKNOWN
Covid19
Nepal Health Research Council
 2021-01-01 PHASE3
NCT04387760 COMPLETED
SARS-CoV 2; COVID-19
Royal College of Surgeons in Ireland - Medical University of Bahrain
 2020-08-11 PHASE2
NCT04981379 COMPLETED
Covid19
Health Institutes of Turkey
 2020-11-16 PHASE3
NCT04392973 COMPLETED
COVID19
King Abdullah International Medical Research Center
 2020-05-21
NCT04529499 TERMINATED
Covid19
Dr. Reddy's Laboratories Limited
 2020-08-22 PHASE3
NCT04411433 UNKNOWN
Sars-CoV2; COVID-19
Ministry of Health, Turkey
 2020-05-08 PHASE3
NCT04600999 COMPLETED
SARS-CoV-2 Infection
University of Pecs
 2020-10-07 PHASE3
NCT04558463 UNKNOWN
Covid19
Indonesia University
 2020-04-16 PHASE3
NCT04358549 COMPLETED
COVID-19
Fujifilm Pharmaceuticals U.S.A., Inc.
 2020-04-17 PHASE2
NCT04351295 COMPLETED
COVID
Tanta University
 2020-04-20 PHASE2; PHASE3
NCT04478448 COMPLETED
Healthy
Genuine Research Center, Egypt
 2020-08-13 PHASE1
NCT04542694 COMPLETED
COVID-19
Promomed, LLC
 2020-05-21 PHASE3
NCT04425460 UNKNOWN
COVID-19
Zhejiang Hisun Pharmaceutical Co. Ltd.
 2020-06 PHASE3
NCT04501783 COMPLETED
COVID-19
R-Pharm
 2020-05-20 PHASE3
NCT04407000 COMPLETED
Bioequivalence
World Medicine ILAC SAN. ve TIC. A.S.
 2020-06-23 PHASE1
NCT04402203 UNKNOWN
COVID-19; Favipiravir (Favipira)
Bangladesh Medical Research Council (BMRC)
 2020-05 PHASE2; PHASE3
NCT04434248 UNKNOWN
COVID-19
Chromis LLC
 2020-04-23 PHASE2; PHASE3
NCT04336904 UNKNOWN
COVID-19
Giuliano Rizzardini
 2020-03-25 PHASE3
NCT04349241 COMPLETED
Coronavirus Disease (COVID-19)
Ain Shams University
 2020-04-18 PHASE3
NCT04333589 UNKNOWN
COVID-19
Peking University First Hospital
 2020-04-01
NCT04359615 UNKNOWN
COVID-19
Shahid Beheshti University of Medical Sciences
 2020-04-20 PHASE4
NCT04310228 UNKNOWN
COVID-19
Peking University First Hospital
 2020-03-08
NCT04319900 UNKNOWN
Novel Coronavirus Pnuemonia
Beijing Chao Yang Hospital
 2020-03-05 PHASE2; PHASE3
NCT04376814 COMPLETED
COVID-19; Favipiravir; Kaletra; Hydroxychloroquine; Lopinavir/Ritonavir
Baqiyatallah Medical Sciences University
 2020-03-29
NCT03394209 COMPLETED
Influenza, Human; Critical Illness; Influenza
Capital Medical University
 2018-02-06 PHASE2
NCT02739477 TERMINATED
Ebola Virus Survivor
Institut National de la Santé Et de la Recherche Médicale, France
 2016-04 PHASE2
NCT02329054 COMPLETED
Ebola Virus Disease
Institut National de la Santé Et de la Recherche Médicale, France
 2014-12 PHASE2
NCT02662855 COMPLETED
Ebola Virus Disease
Beijing Institute of Pharmacology and Toxicology
 2014-11 PHASE2
NCT02026349 COMPLETED
Influenza
MDVI, LLC
 2014-01 PHASE3
NCT02008344 COMPLETED
Influenza
MDVI, LLC
 2013-12 PHASE3
NCT01419457 COMPLETED
Healthy; Hepatic Impairment
MDVI, LLC
 2011-08 PHASE1
NCT01728753 COMPLETED
Influenza
MDVI, LLC
 2012-11 PHASE1; PHASE2
NCT01068912 COMPLETED
Influenza
MDVI, LLC
 2010-02 PHASE2

(data from https://clinicaltrials.gov, updated on 2026-08-07)

Check the Favipiravir (T-705) product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Favipiravir selectively binds to and inhibits viral RNA-dependent RNA polymerase, thereby blocking viral genomic transcription and RNA synthesis within host cells. This potent inhibition halts intracellular viral replication and cellular viral load, underlying its clinical efficacy in mitigating viral pathogenesis across studied indications such as influenza, COVID-19, Lassa fever, and Crimean-Congo hemorrhagic fever.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.